For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...

Tempest Therapeutics, Inc. ( (TPST)) has released its Q3 earnings. Here is a breakdown of the information Tempest Therapeutics, Inc. presented to its investors. Tempest Therapeutics, Inc. is a ...

Tempest Therapeutics (TPST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Building upon a successful end-of-Phase 2 meeting, received FDA "Study May Proceed" letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agree ...

The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic ...

Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company ...

Scotiabank has recently initiated Tempest Therapeutics Inc (TPST) stock to Sector Outperform rating, as announced on March 14, 2024, according to Finviz. Analyst ratings are significant because they ...

Scotiabank has recently initiated Tempest Therapeutics Inc (TPST) stock to Sector Outperform rating, as announced on March 14, 2024, according to Finviz. Analyst ratings are significant because they ...

Shares of Equillium (NASDAQ:EQ) cratered 36% Thursday after the company announced it was pausing certain programs due to partner Ono Pharmaceutical failing to exercise an option to acquire its ...

Tempest Therapeutics Inc (NASDAQ: TPST)’s stock price has gone rise by 0.92 in comparison to its previous close of 1.09, however, the company has experienced a 4.76% increase in its stock price over ...